Osteoporosis Therapeutics - Global Strategic Business Report

Report
340 Pages
April 2024
Region: Global
Global Industry Analysts, Inc
ID: 338510

Global Osteoporosis Therapeutics Market to Reach $15.5 Billion by 2030

The global market for Osteoporosis Therapeutics estimated at US$12.7 Billion in the year 2023, is projected to reach a revised size of US$15.5 Billion by 2030, growing at a CAGR of 2.5% over the analysis period 2023-2030.

Bisphosphonates, one of the segments analyzed in the report, is projected to record 2.7% CAGR and reach US$8.1 Billion by the end of the analysis period. Growth in the Parathyroid Hormone Therapy segment is estimated at 2.1% CAGR for the next 8-year period.

The U.S. Market is Estimated at $5.2 Billion, While China is Forecast to Grow at 4.7% CAGR

The Osteoporosis Therapeutics market in the U.S. is estimated at US$5.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$904.6 Million by the year 2030 trailing a CAGR of 4.7% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.9% and 2.4% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR.

Exciting New Report Features

Full access to influencer engagement stats
Free access to digital archives & research platform. The proprietary platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. The state-of-art tools bring world class market perspectives while protecting participants` privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.
Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities
Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas
Complimentary report updates for one year
Competitor coverage with global market shares of major players
Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies
Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes

What to Expect from the Global Economy in 2024

Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 53 Featured)

Eli Lilly and Company
Genentech, Inc.
Daiichi Sankyo Co., Ltd.
Eisai Co., Ltd.
Novartis Pharmaceuticals Corporation
Chugai Pharmaceutical Co., Ltd.
Novartis International AG
Allergan PLC
Intas Pharmaceuticals Ltd.
Gedeon Richter PLC
F. Hoffmann-La Roche AG
Asahi Kasei Pharma Corporation
Enzo Biochem, Inc.
Bone Biologics Corp.
Mabxience Holding, S.L.

I. METHODOLOGYII. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
World Market Trajectories
A Prelude to Osteoporosis
Growing Geriatric Population and Rising Incidence of Osteoporosis Drive the Global Osteoporosis Market
Developed Regions Dominate the Global Market, Developing to Witness Fastest Growth
Bisphosphonates - The Largest Category of Drugs for Treating Osteoporosis
Approved Drugs for Treatment of Osteoporosis
Select Recent Osteoporosis Drug Approvals
Osteoporosis Therapeutics - Global Key Competitors Percentage Market Share in 2023 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E)

2. FOCUS ON SELECT PLAYERS

Amgen, Inc. (US)
Chugai Pharmaceutical Co., Ltd. (Japan)
Daiichi Sankyo Co., Ltd. (Japan)
Eisai Co., Ltd. (Japan)
Eli Lilly and Company (US)
F. Hoffmann-La Roche Ltd. (Switzerland)
Merck & Co. Inc. (USA)
Novartis International AG (Switzerland)
Pfizer, Inc. (US)
Radius Health, Inc. (USA)

3. MARKET TRENDS & DRIVERS

Growing Incidence of Osteoporosis Augurs Well for Osteoporosis Therapeutics
Global Osteoporosis Prevalence by Country/Region (2012 & 2022P): Number of People with Osteoporosis in Millions for US, EU, Japan, China and India
% of Women Affected by Osteoporosis
Osteoporosis - Factsheet
Osteoporosis in Men
Rising Geriatric Population and the Associated Bone Health Issues to Drive Market Gains
Global Population of 65+ Individuals (In 000s) by Region for the Years 2015, 2020 & 2025
Rising Prevalence of Osteoporosis in Post-menopausal Women Propels Market Growth
Changing Lifestyle Impacting Bone Health
Recommended Daily Intake of Calcium and Vitamin D
Increasing Awareness Related to Osteoporosis Care
New Product Launches Foster Market Growth

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 2: World Historic Review for Osteoporosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 3: World 16-Year Perspective for Osteoporosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
Table 4: World Recent Past, Current & Future Analysis for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 5: World Historic Review for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 6: World 16-Year Perspective for Bisphosphonates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 7: World Recent Past, Current & Future Analysis for Parathyroid Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 8: World Historic Review for Parathyroid Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 9: World 16-Year Perspective for Parathyroid Hormone Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 10: World Recent Past, Current & Future Analysis for Calcitonin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 11: World Historic Review for Calcitonin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 12: World 16-Year Perspective for Calcitonin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 13: World Recent Past, Current & Future Analysis for Selective Estrogen Inhibitors Modulator (SERM) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 14: World Historic Review for Selective Estrogen Inhibitors Modulator (SERM) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 15: World 16-Year Perspective for Selective Estrogen Inhibitors Modulator (SERM) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 16: World Recent Past, Current & Future Analysis for Rank Ligand Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 17: World Historic Review for Rank Ligand Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 18: World 16-Year Perspective for Rank Ligand Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 19: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 20: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 21: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 22: World Recent Past, Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 23: World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 24: World 16-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 25: World Recent Past, Current & Future Analysis for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 26: World Historic Review for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 27: World 16-Year Perspective for Other Routes of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 28: World Osteoporosis Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

UNITED STATES

Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
Table 29: USA Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 30: USA Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 31: USA 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2024 & 2030
Table 32: USA Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 33: USA Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 34: USA 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2014, 2024 & 2030

CANADA

Table 35: Canada Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 36: Canada Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 37: Canada 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2024 & 2030
Table 38: Canada Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 39: Canada Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 40: Canada 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2014, 2024 & 2030

JAPAN

Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
Table 41: Japan Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 42: Japan Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 43: Japan 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2024 & 2030
Table 44: Japan Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 45: Japan Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 46: Japan 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2014, 2024 & 2030

CHINA

Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
Table 47: China Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 48: China Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 49: China 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2024 & 2030
Table 50: China Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 51: China Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 52: China 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2014, 2024 & 2030

EUROPE

Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
Table 53: Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 54: Europe Historic Review for Osteoporosis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 55: Europe 16-Year Perspective for Osteoporosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
Table 56: Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 57: Europe Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 58: Europe 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2024 & 2030
Table 59: Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 60: Europe Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 61: Europe 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2014, 2024 & 2030

FRANCE

Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
Table 62: France Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 63: France Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 64: France 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2024 & 2030
Table 65: France Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 66: France Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 67: France 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2014, 2024 & 2030

GERMANY

Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
Table 68: Germany Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 69: Germany Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 70: Germany 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2024 & 2030
Table 71: Germany Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 72: Germany Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 73: Germany 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2014, 2024 & 2030

ITALY

Table 74: Italy Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 75: Italy Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 76: Italy 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2024 & 2030
Table 77: Italy Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 78: Italy Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 79: Italy 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2014, 2024 & 2030

UNITED KINGDOM

Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
Table 80: UK Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 81: UK Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 82: UK 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2024 & 2030
Table 83: UK Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 84: UK Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 85: UK 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2014, 2024 & 2030

REST OF EUROPE

Table 86: Rest of Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 87: Rest of Europe Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 88: Rest of Europe 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2024 & 2030
Table 89: Rest of Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 90: Rest of Europe Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 91: Rest of Europe 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2014, 2024 & 2030

ASIA-PACIFIC

Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
Table 92: Asia-Pacific Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 93: Asia-Pacific Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 94: Asia-Pacific 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2024 & 2030
Table 95: Asia-Pacific Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 96: Asia-Pacific Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 97: Asia-Pacific 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2014, 2024 & 2030

REST OF WORLD

Table 98: Rest of World Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 99: Rest of World Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 100: Rest of World 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2024 & 2030
Table 101: Rest of World Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 102: Rest of World Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 103: Rest of World 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2014, 2024 & 2030

IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Eli Lilly and Company
Genentech, Inc.
Daiichi Sankyo Co., Ltd.
Eisai Co., Ltd.
Novartis Pharmaceuticals Corporation
Chugai Pharmaceutical Co., Ltd.
Novartis International AG
Allergan PLC
Intas Pharmaceuticals Ltd.
Gedeon Richter PLC
F. Hoffmann-La Roche AG
Asahi Kasei Pharma Corporation
Enzo Biochem, Inc.
Bone Biologics Corp.
Mabxience Holding, S.L.

Table Information

Report Attribute	Details
No. of Pages	340
Published	April 2024
Forecast Period	2023 - 2030
Estimated Market Value ( USD ) in 2023	$ 12.7 Billion
Forecasted Market Value ( USD ) by 2030	$ 15.5 Billion
Compound Annual Growth Rate	2.9%
Regions Covered	Global

PURCHASE OPTIONS

Single User License PDF

1 - 10 User License PDF

Enterprise License PDF

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5293EUR$5,450USD£4,566GBP
1 - 10 USER LICENSE PDF	The product is a PDF.	This is a 1-10 user license, allowing up to ten users have access to the product.	€10057EUR$10,355USD£8,676GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€15880EUR$16,350USD£13,699GBP

Global Osteoporosis Therapeutics Market to Reach $15.5 Billion by 2030

The U.S. Market is Estimated at $5.2 Billion, While China is Forecast to Grow at 4.7% CAGR

Exciting New Report Features

What to Expect from the Global Economy in 2024

Select Competitors (Total 53 Featured)

Table of Contents

Companies Mentioned (Partial List)

Table Information

Related Topics

Related Reports

Osteoporosis Drugs Market, Size, Share, Global Forecast 2023-2030, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis

Osteoporosis Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Osteoporosis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Osteoporosis Treatment Global Market Report 2024

Global Osteoporosis Drugs Market by Drug Type (Bisphosphonates, Calcitonin, Parathyroid Hormone Therapy), Route of Administration (Injectable, Oral), Application - Forecast 2024-2030